These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26139286)

  • 1. ESKAPEing the labyrinth of antibacterial discovery.
    Tommasi R; Brown DG; Walkup GK; Manchester JI; Miller AA
    Nat Rev Drug Discov; 2015 Aug; 14(8):529-42. PubMed ID: 26139286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and challenges in implementing the research on ESKAPE pathogens.
    Rice LB
    Infect Control Hosp Epidemiol; 2010 Nov; 31 Suppl 1():S7-10. PubMed ID: 20929376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial Resistance in ESKAPE Pathogens.
    De Oliveira DMP; Forde BM; Kidd TJ; Harris PNA; Schembri MA; Beatson SA; Paterson DL; Walker MJ
    Clin Microbiol Rev; 2020 Jun; 33(3):. PubMed ID: 32404435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
    Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
    Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections.
    Younis W; Thangamani S; Seleem MN
    Curr Pharm Des; 2015; 21(28):4106-11. PubMed ID: 25961308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview perspective of bacterial resistance.
    Furtado GH; Nicolau DP
    Expert Opin Ther Pat; 2010 Oct; 20(10):1273-6. PubMed ID: 20687782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile.
    Rajamuthiah R; Jayamani E; Majed H; Conery AL; Kim W; Kwon B; Fuchs BB; Kelso MJ; Ausubel FM; Mylonakis E
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5203-7. PubMed ID: 26459212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of the ESKAPE pathogens.
    Pendleton JN; Gorman SP; Gilmore BF
    Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel antibacterial drugs to combat multiple resistant organisms.
    Bassetti M; Righi E
    Langenbecks Arch Surg; 2015 Feb; 400(2):153-65. PubMed ID: 25667169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
    Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
    [No Abstract]   [Full Text] [Related]  

  • 11. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
    Behroozian S; Svensson SL; Davies J
    mBio; 2016 Jan; 7(1):e01842-15. PubMed ID: 26814180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogens resistant to antibacterial agents.
    Chen LF; Chopra T; Kaye KS
    Infect Dis Clin North Am; 2009 Dec; 23(4):817-45, vii. PubMed ID: 19909886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance patterns among nosocomial pathogens: trends over the past few years.
    Jones RN
    Chest; 2001 Feb; 119(2 Suppl):397S-404S. PubMed ID: 11171776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now.
    Freire-Moran L; Aronsson B; Manz C; Gyssens IC; So AD; Monnet DL; Cars O;
    Drug Resist Updat; 2011 Apr; 14(2):118-24. PubMed ID: 21435939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges.
    Jampilek J
    Curr Med Chem; 2018; 25(38):4972-5006. PubMed ID: 28925868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.